Stilla Technologies with Source BioScience brings advanced genomics solutions to the UK market
Cambridge, UK – Stilla Technologies, a global leader in digital PCR (dPCR) solutions, announces a strategic partnership with Source BioScience, a leading UK-based genomics service provider.
New Blog: What is Olink Proteomics?
Proteomics is a cutting-edge research area that examines proteins.
New blog: What are the benefits of digital pathology?
Digital pathology is used within pathology, computer science and image analysis and is transforming how pathologists diagnose and research diseases. Within this article, we will conduct a deep dive into the benefits of digital pathology.
New Blog: Revolutionising Early-Stage Breast Cancer Treatment
Revolutionising Early-Stage Breast Cancer Treatment: How the MAF Test® Enhances Precision Care with Biomarker-Driven InsightsThe MAF Test® by Inbiomotion is an advanced diagnostic tool designed to enhance treatment decisions in early-stage breast cancer.
New blog: How can you benefit from outsourcing sequencing services?
Sanger sequencing is utilised to understand the arrangement of nucleotides within a sequence of DNA. This technique offers 99.99% reliability, enhanced sensitivity due to its sequencing depth, and the ability to provide sequencing information from even the most deteriorated DNA samples.
New blog: how do cellular pathology services fit into the patient pathway?
This article aims to dissect the integration of cellular pathology services within the patient pathway.
NGS v Sanger Sequencing
DNA sequencing, the process of delineating the order of bases (A, C, T, G) in a section of DNA, was first carried out in the 1970s.
Why Choose AVITI for Mid-Throughput Sequencing?
At Source Genomics, a part of Source BioScience, we understand the critical role that cutting-edge genomic sequencing technology plays in advancing scientific research and clinical diagnostics. The AVITI System by Element Biosciences represents a leap forward in our mission to provide our clients with the most effective solutions.
What are the Four Main Steps of Next-Gen Sequencing? New Blog from Source BioScience
Next-generation sequencing (NGS) rapidly sequences DNA/RNA using massively parallel sequencing technologies. The process of next-gen sequencing starts with fragmenting DNA, adding adapters, and amplifying fragments.
Introducing SpeedREAD™ Service
Your local laboratory for rapid Whole Plasmid Nanopore Sequencing results.
A blog on comparing RNA Sequencing techniques
RNA sequencing is becoming the gold-standard method for uncovering the cellular mechanisms behind disease. A variety of RNA sequencing techniques have evolved, which provide all-important information on disease causes and progression for more effective treatments.
Do you have a histopathology reporting backlog?
Source LDPath is a flexible and trusted extension to your histopathology laboratory, supporting you to accelerate turnaround times for reporting and decrease backlogs.
Source LDPath launch new improved courier service
Source LDPath have further optimised their histopathology courier service to improve on their already market-leading turnaround times. The new and improved courier network has recently launched and will fully replace old courier routes by Monday, May 20th 2024.
Reveal structural variation in a way that's never been done before
Optical genome mapping (OGM) is a workflow that combines various technologies for one purpose: to reveal structural variation in a way that’s never been done before.
Inbiomotion and Source BioScience sign an exclusive agreement for MAF Test® in United Kingdom and Ireland
This pioneering test aids oncologists in predicting recurrence and survival rates in breast cancer patients and potential treatment eligibility to bisphosphonates Results showing the clinical utility of the test have been published in Lancet Oncology and the Journal of National Can
Source Genomics expands sequencing portfolio with first UK commercial service on the Element Biosciences AVITI™ System
Cambridge, UK - Source Genomics, a part of the Source BioScience Group, announces their genomic laboratory expansion by adding an Element Biosciences AVITI™ System to its fleet of sequencers.
Source Genomics White Paper explores the transformative power of multi-omics in genomic research
Multiomics combines the various ‘omics disciplines that make up the complex landscape of life science research.
Optical Genome Mapping shines light on complex structural variants in Genome
Unlock a 25% discount today on all OGM services with Source Genomics, limited time only.
Source Genomics expands rapid Sanger sequencing services to the North of the UK
Cambridge, UK - Source Genomics, a part of the Source BioScience Group, announces their genomic laboratory expansion into the North of the UK for increased capacity of its Sanger sequencing services leading to faster turnaround times for data delivery.
Source LDPath Wins 2023 MedTech Breakthrough Award
Source LDPath's wins MedTech Breakthrough Award 2023 for "Best Hospital Technology Implementation" following the clinical success of their digital integration with East Kent Hospital NHS Foundation Trust.
Source BioScience expands genomic footprint
Source BioScience signals growth with the opening of new Cambridge Genomics and Precision Medicine Unit.
Leading UK Diagnostics provider Source LDPath expands AI capabilities with Ibex Medical Analytics
NHS Trusts Gain Access to Galen, Ibex's Multi-tissue AI Platform, Supporting Pathologists with Enhanced Diagnostic Accuracy and Efficiency
Ground-breaking digital approach helps cut pathology waiting times
An innovative partnership between East Kent Hospitals and digital pathology company Source LDPath, a part of SourceBio International plc, is helping to reduce pathology waiting times and improve patient care.
Source BioScience completes £18.5m strategic acquisition of LDPath Ltd to reimagine the future of pathology by combining cellular and digital pathology platforms
SourceBio International plc, a leading international provider of integrated state-of-the-art laboratory services and products, announces that it has agreed to purchase the entire issued capital of LDPath Limited (“LDP”), a London based leader in Digital Pathology testing services.